Merck (NYSE: MRK) terminates Covid-19 vaccine development programme 

  • January 26, 2021 03:26 PM AEDT
  • Kunal Sawhney
    CEO Kunal Sawhney
    2781 Posts

    Kunal Sawhney is founder & CEO at Kalkine and is a richly experienced and accomplished financial professional with a wealth of knowledge in the Australian Equities Market. Kunal obtained a Master of Business Administration degree from University of T...

Merck (NYSE: MRK) terminates Covid-19 vaccine development programme 

Summary

  • Merck & Co Inc discontinued its Covid-19 vaccine development programme following inferior results in Phase 1 clinical trials.
  • The company has said it will be continuing with the development of therapeutic treatments and the research on SARS-CoV-2/Covid-19.
Gold MTF non-AMP

New Jersey-headquartered pharmaceutical giant Merck and Co. Inc (NYSE: MRK) said on Monday, 25 January, that it has terminated its Covid-19 (SARS-CoV-2) vaccine development programme. The decision to discontinue the vaccine programme is based on some findings from its Phase-1 clinical trials.  

Vaccine programme halted 

The immune responses shown by the volunteers in the Phase 1 trials were inferior as compared to the reported response for other Covid-19 vaccines, which have received approvals for emergency usage.  

However, the Covid-19 vaccine candidates -- V590 and V591 -- were generally well tolerated in the studies, Merck said.  

The results of Phase 1 clinical studies for the discontinued vaccine candidates are likely to be submitted by Merck and its collaborators for publication in a peer reviewed journal.

Merck has decided to record the charge due to discontinuation of Covid-19 vaccine candidates in the results of Q4 2020, the company said.  

Speaking about the development, Dr. Dean Y. Li, president, Merck Research Laboratories said

the company is grateful to all the volunteers who participated in Merck’s vaccine trials and the collaborators who were working on these vaccine candidates. 

Shares slip in pre-market 

Following the development, Merck shares slipped a little more than 1 per cent in the pre-market trades on the New York Stock Exchange on Monday.  

According to the data available with NYSE, the stock of Merck & Co last closed at $80.98, down 0.25 per cent, on Friday, and has lost 1.02 per cent in the pre-market session on Monday, 25 January.  

Merck & Co shares (1-month performance) 

(Source: Refinitiv, Thomson Reuters) 

Research and treatment development to continue 

Following the unexpected discontinuation of the Merck’s Covid-19 vaccine candidates, the drugmaker has said it is aiming to focus its research strategy and production capabilities on advancing two treatments for Covid-19.  

One of the two therapeutic treatments that are being developed by Merck include a medicine dedicated for hospitalised and vulnerable patients, which reduces the over-response of immune systems to the coronavirus.  

The second is an antiviral medicine that is being matured with an objective of lowering the effect of SARS-CoV-2 virus. The latter has already exhibited promising results in the clinical phase of ongoing studies.  

Meanwhile, Merck has said the company will be scaling up the manufacturing and advancing the clinical programmes for two of its investigational medicines, MK-7110 and MK-4482, being developed in collaboration with Ridgeback Bio. Additionally, the company will be continuing research on SARS-CoV-2/COVID-19.  

Merck’s therapeutic treatments for Covid-19 

The therapeutic candidate of Merck MK-7110 has emerged as more than 50 per cent effective in reducing the risk of death or a respiratory failure in hospitalised patients with moderate to severe Covid-19 infection, the interim results from a Phase 3 clinical study showed.  

MK-7110 is primarily a recombinant fusion protein that targets the novel immune pathway checkpoint, modulating the inflammatory response to SARS-CoV-2 virus. On the other hand, MK-4482 is currently under investigation in Phase 2/3 clinical studies in both out-patient departments as well as in the hospital.  

Merck is planning to release the initial efficacy data in Q1 2021, while the primary completion data of Phase 2/3 clinical trials in May. Notably, the full results for the former antibody are also expected in the first quarter this year.  

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK